Clinical TrialMay 18, 2026, 08:02 AM
BioVie Completes Phase 2 Parkinson's Trial; Topline Results Q3 2026
AI Summary
BioVie Inc. announced the completion of the last patient evaluation visit for its SUNRISE-PD Phase 2 trial, evaluating its drug candidate bezisterim in early-stage Parkinson’s disease. The company anticipates announcing topline results in Q3 2026. This trial, which randomized 57 patients, was designed to assess bezisterim’s therapeutic impact on motor and non-motor endpoints to finalize the design for Phase 3 registrational trials. BioVie also highlighted a recent virtual key opinion leader event discussing insulin resistance and bezisterim's mechanism of action.
Key Highlights
- Last patient evaluation visit completed for SUNRISE-PD Phase 2 trial.
- Topline results for Parkinson's disease trial expected in Q3 2026.
- SUNRISE-PD trial randomized 57 patients 1:1 to bezisterim or placebo.
- Patients received 20 mg of bezisterim or placebo twice daily for 12 weeks.
- Bezisterim is also being studied in approximately 200 patients for Long COVID.
- Long COVID trial topline data expected late summer 2026.
Price Impact
More from BIVI